PT3247719T - Proteínas agonistas do receptor met - Google Patents

Proteínas agonistas do receptor met

Info

Publication number
PT3247719T
PT3247719T PT167013127T PT16701312T PT3247719T PT 3247719 T PT3247719 T PT 3247719T PT 167013127 T PT167013127 T PT 167013127T PT 16701312 T PT16701312 T PT 16701312T PT 3247719 T PT3247719 T PT 3247719T
Authority
PT
Portugal
Prior art keywords
receptor agonist
met receptor
agonist proteins
proteins
met
Prior art date
Application number
PT167013127T
Other languages
English (en)
Inventor
Vicogne Jerome
Melnyk Oleg
Ollivier Nathalie
Adriaenssens Eric
Leclercq Berenice
Simonneau Claire
De Nola Giovanni
Gherardi Ermanno
De Jonge Hugo
Original Assignee
Univ Degli Studi Di Pavia
Centre Nat Rech Scient
Pasteur Institut
Universita© De Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Di Pavia, Centre Nat Rech Scient, Pasteur Institut, Universita© De Lille filed Critical Univ Degli Studi Di Pavia
Publication of PT3247719T publication Critical patent/PT3247719T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4753Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1833Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
PT167013127T 2015-01-21 2016-01-21 Proteínas agonistas do receptor met PT3247719T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15152027 2015-01-21

Publications (1)

Publication Number Publication Date
PT3247719T true PT3247719T (pt) 2019-12-23

Family

ID=52434559

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167013127T PT3247719T (pt) 2015-01-21 2016-01-21 Proteínas agonistas do receptor met

Country Status (11)

Country Link
US (1) US10435450B2 (pt)
EP (1) EP3247719B1 (pt)
JP (1) JP6944875B2 (pt)
CN (1) CN107531770B (pt)
CA (1) CA2973300C (pt)
DK (1) DK3247719T3 (pt)
ES (1) ES2761852T3 (pt)
HU (1) HUE047148T2 (pt)
PL (1) PL3247719T3 (pt)
PT (1) PT3247719T (pt)
WO (1) WO2016116577A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
US20060003931A1 (en) * 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor and methods of use
KR20080082629A (ko) * 2005-11-10 2008-09-11 리셉터 바이오로직스 인크 간세포 성장인자 인트론 융합 단백질
US20090215686A1 (en) 2007-03-05 2009-08-27 Huaqiang Eric Xu Nk1-based polypeptides and related methods
US20090202606A1 (en) 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
CA2720611C (en) 2008-04-09 2016-07-12 Viromed Co., Ltd. Lyophilized dna formulations for enhanced expression of plasmid dna
WO2011103382A2 (en) 2010-02-22 2011-08-25 The Brigham And Women's Hospital Compositions and methods for inducing angiogenesis
US9556248B2 (en) 2010-03-19 2017-01-31 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
US9963493B2 (en) 2011-11-03 2018-05-08 Viromed Co., Ltd. Gene therapy for diabetic neuropathy using an HGF isoform

Also Published As

Publication number Publication date
ES2761852T3 (es) 2020-05-21
US10435450B2 (en) 2019-10-08
CA2973300A1 (en) 2016-07-28
CA2973300C (en) 2024-03-19
HUE047148T2 (hu) 2020-04-28
US20170369545A1 (en) 2017-12-28
WO2016116577A1 (en) 2016-07-28
PL3247719T3 (pl) 2020-07-13
JP6944875B2 (ja) 2021-10-06
EP3247719A1 (en) 2017-11-29
CN107531770A (zh) 2018-01-02
JP2018508197A (ja) 2018-03-29
DK3247719T3 (da) 2019-12-16
CN107531770B (zh) 2021-10-08
EP3247719B1 (en) 2019-09-25

Similar Documents

Publication Publication Date Title
ZA201802261B (en) Polypeptides
ZA201802371B (en) Glucagon receptor agonists
GB201514875D0 (en) Receptor
HK1250041A1 (zh) 多肽
HK1252163A1 (zh) 受體
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
GB201717974D0 (en) Modified receptors
GB201508180D0 (en) Antibodies
GB2551945B (en) Novel GLP-1 receptor agonist peptides
ZA201704366B (en) Il-17a-binding polypeptides
HK1250040A1 (zh) 多肽
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
GB201513033D0 (en) Proteins
GB201522610D0 (en) Protein
GB201517390D0 (en) Protein variant analysis
GB201503438D0 (en) Antibodies
HUE047148T2 (hu) MET receptor antagonista proteinek
GB201515744D0 (en) Proteins
GB201503778D0 (en) Proteins
GB201515337D0 (en) Protein Expression
GB201507541D0 (en) Antibodies
GB201504858D0 (en) Antibodies
GB201500297D0 (en) Agonists